Good news for Health Canada patients: Seattle Genetics has approved ADCETRIS as post-autologous stem cell transplant (ASCT) postremission therapy for patients affected by Hodgkin lymphoma (HL) who are a higher risk of advancement or relapse. Positive results from phase three AETHREA clinical trials helped to approve the medication. Clay Siegall, President and Chief Executive Officer of Seattle Genetics says with the expanding of the ADCETRIS label, Canadian doctors and patients will have more access to treat their HL. He says this is a great milestone toward expanding ADCETRIS availability globally to patients who need this important medication.
There are numerous warnings and precautions for patients who take or are considering taking ADCETRIS, including a boxed warning of progressive multifocal leukoencephalopathy (PML). For additional Important Safety Information, see the full Prescribing Information for ADCETRIS at www.seattlegenetics.com or www.ADCETRIS.com.